Canton Biologics Completes Over 300 Million Yuan Series C Financing, Led By Sdic Venture Capital
09/18/23, 9:59 AM
Location
guangzhouIndustry
biotechnology
manufacturing
Round Type
series c
Investors
Chnin Financial, Taipu Life Science Investment, Guangdong Technology Financial Group, Sdic Venture Capital
On September 13th, Canton Biologics Co., Ltd. announced that it had recently completed a Series C financing round exceeding 300 million yuan. This round of financing was led by SDIC Venture Capital, with participation from Guangdong Technology Financial Group, Taipu Life Science Investment, and Chnin Financial. The funds raised in this round will be channeled towards advancing the company's R&D in novel biotechnologies, scaling commercial production capabilities, and expanding its global strategic footprint.
Company Info
Location
guangzhou, guangdong province, china
Additional Info
Canton Biologics is the biggest Contract Development Manufacture Organization in the South China, providing the one-stop integrated solutions that meet international regulatory standards and cover early discovery to commercialization for global innovative pharmaceutical enterprises.
CMC：Leading End-to-End Biologics CMC platform，including Antibody Optimization, Cell Line and Process Development, Physiochemical, Biochemical, Characterization, Tech-Transfer and Clinical Bioanalysis
commercial manufacturing：12+4 manufacturing lines complying with China, US and EU GMP standard, 50-2000L (batch, fed-batch, perfusion) DS and DP manufacturing
We proudly provide premium development and production service for more than 100 customers, these successful projects include antibodies,fusion proteins,recombinant proteins, recombinant vaccines, microecological, Cell and Gene therapy and other biopharmaceuticals.
With the values of "Reliable Efficient Innovative", we help the global biotech to improve efficiency of R&D significantly, and to reduce the costs of R&D and manufacturing.